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Abstract
Background and Aims: Chronic hepatitis C (HCV) is a liver disease affecting over 3 million Americans. Liver biopsy is the
gold standard for assessing liver fibrosis and is used as a benchmark for initiating treatment, though it is expensive and
carries risks of complications. FibroTest is a non-invasive biomarker assay for fibrosis, proposed as a screening alternative to
biopsy.
Methods: We assessed the cost-effectiveness of FibroTest and liver biopsy used alone or sequentially for six strategies
followed by treatment of eligible U.S. patients: FibroTest only; FibroTest with liver biopsy for ambiguous results; FibroTest
followed by biopsy to rule in; or to rule out significant fibrosis; biopsy only (recommended practice); and treatment without
screening. We developed a Markov model of chronic HCV that tracks fibrosis progression. Outcomes were expressed as
expected lifetime costs (2009 USD), quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios (ICER).
Results: Treatment of chronic HCV without fibrosis screening is preferred for both men and women. For genotype 1
patients treated with pegylated interferon and ribavirin, the ICERs are $5,400/QALY (men) and $6,300/QALY (women)
compared to FibroTest only; the ICERs increase to $27,200/QALY (men) and $30,000/QALY (women) with the addition of
telaprevir. For genotypes 2 and 3, treatment is more effective and less costly than all alternatives. In clinical settings where
testing is required prior to treatment, FibroTest only is more effective and less costly than liver biopsy. These results are
robust to multi-way and probabilistic sensitivity analyses.
Conclusions: Early treatment of chronic HCV is superior to the other fibrosis screening strategies. In clinical settings where
testing is required, FibroTest screening is a cost-effective alternative to liver biopsy.
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Introduction
Viral hepatitis C (HCV) is a serious liver disease affecting 180
million people worldwide [1]. In the U.S., 1.3% to 1.9% of the
population has been infected with HCV, and 2.7 to 3.9 million
people live with chronic infection [2]. Chronic HCV causes liver
fibrosis, cirrhosis, and hepatocellular carcinoma (HCC), and is the
most common cause of liver transplantation in the US [1].
Current practice guidelines in the U.S. recommend treatment
for chronic HCV patients with significant fibrosis progression [1].
For pre-treatment evaluations of patients, liver biopsy is the
current gold standard to ascertain liver histology and measure
fibrosis progression. However, its expense, risk of side-effects, and
potential inaccuracy from sampling and observation errors reduce
its utility for frequent liver fibrosis screening [3,4,5]. Non-invasive
tests of liver fibrosis – including serum markers such as FibroTest
(FibroSure) and imaging methods such as FibroScan (transient
elastography) – offer potentially viable alternatives [6]. These tests
are clinically validated in most common liver diseases caused by
hepatitis C, hepatitis B, and alcohol abuse.
Few published studies have addressed the cost-effectiveness of
non-invasive tests as alternatives to liver biopsy for determining
when to initiate treatment for HCV. A number of studies have
investigated test characteristics; some have estimated at a threshold
of 0.3, sensitivities and specificities of FibroTest of 74–82% and
57–65% [6], respectively, though this changes with the definition
of underlying disease and FibroTest cutoff; others have examined
the cost-effectiveness of various treatment options, though gene-
rally without considering combinations of screening and treat-
ment. One existing cost-effectiveness analysis of non-invasive
screening tests fails to adhere to recommended standards including
evaluating options over a lifetime horizon and including quality-of-
life considerations [7,8]. Consequently uncertainties remain about
the indications, accuracy, and cost-effectiveness of FibroTest and
other non-invasive liver fibrosis screening technologies [3].
Furthermore, recent development in new protease inhibitors to
PLoS ONE | www.plosone.org 1 December 2011 | Volume 6 | Issue 12 | e26783treat HCV, such as telaprevir (Incivek
TM, Vertex), used in
conjunction with pegylated interferon and ribavirin, have
significantly improved treatment success rates compared to the
standard treatment [9]. The cost-effectiveness of the new
treatment is unknown.
We performed a model-based cost-effectiveness analysis of six
FibroTest and liver biopsy screening strategies followed by
treatment for eligible U.S. chronic HCV patients. We assessed
FibroTest’s viability as a tool to determine when to initiate
treatment by addressing the questions: How should FibroTest be
used in the context of chronic HCV, if at all? And how should




The Markov model simulates the lifetime disease progression of
a cohort of treatment-naı ¨ve men and women who have chronic
HCV infections with various stages of liver fibrosis. Progression
through fibrosis stages is characterized by the Metavir Scoring
system, with possible transitions occurring every 6 months. States
include healthy (HCV negative), no fibrosis (F0), portal fibrosis
with no septa (F1), portal fibrosis with few septa (F2), numerous
septa without cirrhosis (F3), compensated cirrhosis (F4), decom-
pensated cirrhosis (DC), HCC, and liver transplant. Without
treatment, complete recovery (returning to the healthy state) is
only possible from F0. A proportion of patients who start at F0 are
‘‘non-progressors’’ and do not progress to more severe fibrosis
stages. A proportion of patients with decompensated cirrhosis and
with HCC receive liver transplants. Death can occur from any
state (Figure 1). The model extends a prior, empirically calibrated,
model [10]. In the base case, starting age in the model is 40 years
old with cohorts age 40 through 70 considered in sensitivity
analyses.
We considered six strategies aimed at detecting fibrosis and
beginning treatment to prevent liver disease and death [8,11]. The
strategies considered (Figure 2) are:
(A) FibroTest Only. Patients are screened by FibroTest. If
the test score is less than 0.31 (mild fibrosis, F0–F1), then repeat
FibroTest annually. If the score is between 0.31 and 0.58
(intermediate), then repeat FibroTest every six months. If the
test score is greater than 0.58 (significant fibrosis, F2–F4), then
begin treatment with no liver biopsy in patients without medical
contraindication.
(B) FibroTest and Biopsy. Patients are screened by
FibroTest. If the test score is less than 0.31, then repeat
FibroTest annually with no liver biopsy. If the test score is
between 0.31 and 0.58, then follow up with liver biopsy. If liver
biopsy indicates significant fibrosis, then begin treatment in
patients without medical contraindication. If liver biopsy
indicates mild fibrosis, then restart the testing strategy annually.
If the test score is greater than 0.58, then begin treatment with no
liver biopsy in patients without medical contraindication.
(C) FibroTest Rule In. Patients are screened by FibroTest. If
the test score is less than 0.58, then repeat FibroTest annually with
no liver biopsy. If the test score is greater than or equal to 0.58,
then follow up with liver biopsy. If liver biopsy indicates significant
fibrosis, then begin treatment in patients without medical
contraindication. If liver biopsy indicates mild fibrosis, then
restart testing strategy annually.
(D) FibroTest Rule Out. Patients are screened by FibroTest.
If the test score is less than 0.31, then repeat FibroTest annually
with no liver biopsy. If the test score is greater than or equal to
0.31, then follow up with liver biopsy. If liver biopsy indicates
significant fibrosis, then begin treatment in patients without
medical contraindication. If liver biopsy indicates mild fibrosis,
then restart testing strategy annually.
(E) Liver Biopsy Only (currently recommended prac-
tice). All patients receive liver biopsy. Those with results
showing significant fibrosis without medical contraindication are
treated, otherwise they are re-biopsied every 3 years.
(F) Immediate Treatment. All patients without medical
contraindication are treated without screening for fibrosis.
Do Nothing (HCV natural progression without fibrosis
screening or treatment) is only considered in the context of
sensitivity analyses.
Standard treatment includes peginterferon alfa (2a or 2b) and
ribavirin for 48 weeks for genotype 1 patients and 24 weeks for
patients with genotypes 2 or 3. For genotype 1, an assessment of
early viral response (EVR) is modeled at 12 weeks. EVR is defined
as a 2 log reduction or complete absence of serum HCV RNA at
week 12 of treatment compared with the baseline level. Failure to
achieve an EVR is the most accurate predictor of not achieving
Figure 1. HCV Natural History Model.
doi:10.1371/journal.pone.0026783.g001
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treatment and resume fibrosis progression. Patients who have
undergone complete treatment and achieved SVR transition to a
recovered health states stratified by fibrosis severity, and other
patients resume fibrosis progression. SVR is defined as the absence
of HCV RNA from serum 24 weeks following discontinuation of
treatment. (Figure 3 A, C)
We also examined the cost-effectiveness of fibrosis screening in
the presence of a new HCV protease inhibitor — telaprevir
(Incivek
TM Pharmaceuticals) — for treatment naı ¨ve genotype 1
Figure 2. Model Structure; Six Strategies: (A) FibroTest Only; (B) FibroTest and Biopsy; (C) FibroTest Rule-In; (D) FibroTest Rule-Out;
(E) Liver Biopsy Only; (F) Immediate Treatment. Note: Panels A–F represent separate clinical strategies that we compare by applying them in
our natural history model. ‘‘Die’’ in the figures is to highlight the possibility of death from liver biopsy.
doi:10.1371/journal.pone.0026783.g002
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PLoS ONE | www.plosone.org 3 December 2011 | Volume 6 | Issue 12 | e26783Figure 3. Treatment Sub-tree: (A) Genotype 1 (Standard Treatment); (B) Genotype 1 (Triple Therapy); (C) Genotypes 2 and 3. Note:
‘‘Die’’ in the figures is to highlight the possibility of death from treatment.
doi:10.1371/journal.pone.0026783.g003
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Patients receive a 12 weeks course of telaprevir with peginterferon
and ribavirin, followed by peginterferon and ribavirin alone for
either 12 or 36 weeks depending on extended rapid viral response
(eRVR). eRVR is defined as undetectable HCV RNA at week 4
and week 12 (Figure 3 B).
For each strategy, we calculated discounted quality-adjusted life
expectancy and total lifetime costs, comparing strategies with
incremental cost-effectiveness ratios.
Data and Sources
We estimated model parameters from extensive review of the
published literature and expert opinions.
Fibrosis
We found wide variations in the literature for the initial
distribution of fibrosis stages for chronic HCV patients presented
at treatment evaluations. Given the lack of nationally represen-
tative data for the US, we derived the prevalence of each fibrosis
stage from a large cohort of urban HCV patients (Detroit,
Michigan), with 18% F0, 24% F1, 17% F2, 13% F3, 28% F4, and
varied the prevalence over a broad range in sensitivity analyses
[12].
Epidemiology
Empirical studies that accurately characterize all phases of
HCV natural history and fibrosis progression are lacking due to
the asymptomatic acute infection period and long duration (20 to
40 years) between initial infection and progression to end-stage
liver disease [1,10,13,14]. Estimates of liver fibrosis progression
rates for chronic HCV are heterogeneous [15]. Calibration of a
model of HCV to infection prevalence and mortality from liver
cancer in the U.S. yields plausible progression rates [16] (see
section I in Appendix S1). We incorporated these calibrated rates
(stratified by age and gender) in our analysis, and employed the
upper and lower ranges in sensitivity analyses (Table 1). Mortality
rates from causes other than HCV were derived from 2004 U.S.
life tables [17].
FibroTest Characteristics
FibroTest is a risk algorithm based on a panel of six blood
serum biochemical markers combined with a patient’s age and
Table 1. Model Parameter Values: Epidemiology and Cohort Assumptions.*
Base Min Max Source
Proportion of F0 patients who are non-progressors 0.2420 0.0960 0.7410 [10]
6 months transition probabilities relating to fibrosis progression [10,16]
Remission (from F0) 0.0060 0.0035 0.0085
F4 to decompensated cirrhosis (DC) 0.0198 0.0159 0.0247
Cirrhosis (both F4 and DC) to HCC 0.0104 0.0085 0.0139
Progression, men by age [10,16]
40–49 0.0266 0.0134 0.0464
50–59 0.0606 0.0358 0.0773
60–69 0.1046 0.0606 0.1601
$70 0.1397 0.0732 0.2126
Progression, women by age [10,16]
40–49 0.0139 0.0065 0.0286
50–59 0.0320 0.0139 0.0564
60–69 0.0554 0.0208 0.1113
70–79 0.0741 0.0397 0.1298
$80 0.0997 0.0416 0.1626
Liver transplant 6 month probability [49]
Liver transplant from DC 0.0253 0 0.2254
Liver transplant from HCC 0.0780 0.0253 0.2254
Disease mortality (6 month rate)
Liver transplant mortality 0.0760 0.0719 0.0807 [50]
Post liver transplant mortality 0.0256 0.0250 0.0260 [50]
Decompensated cirrhosis mortality 0.1530 0.0645 0.1975 [10]
HCC mortality 0.2165 0.1595 0.2495 [10]
Liver biopsy mortality (use as probability) 0.0003 0 0.0033 [51]
Treatment mortality (annual rate) 0.0005 0.00025 0.0008 [52]
Cohort starting age
a 40 40 70 Assumed
Discount rate (annual) 0.03 0 0.05 [7]
*All references included in Table 1–3 are from published literature unless explicitly stated as our assumptions.
aWe run the same model with cohorts at different starting age to identify the most cost-effective strategy at each age.
doi:10.1371/journal.pone.0026783.t001
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manufacturer suggests that a score below 0.31 indicates mild
fibrosis (F0–F1); 0.32 and 0.58 indicates F1 to F2; and above 0.58
indicates significant fibrosis (F2–F4) [18]. We obtained test
characteristics [19] and defined plausible ranges for these test
characteristics based on published studies [6,20,21,22,23,24,
25,26,27]. (Table 2)
Treatment Response
A longitudinal study of peginterferon alfa-2b and ribavirin for
chronic HCV patients who have undergone EVR assessment at 12
weeks provided the probability of achieving EVR and the
probability of SVR for those who achieved EVR [28]. For the
new HCV drug telaprevir, we used effectiveness data from the
Phase III ADVANCE study [9]. (Table 2)
Patients’ initiation of and adherence to treatment can influence
the optimal disease management strategy. We modeled full
treatment initiation assuming our target population consisted of
patients without treatment contraindication. The percentage of
eligible patients was varied in sensitivity analysis as research has
shown many patients with HCV are not currently treated for
reasons including medical and psychiatric co-morbidities, sub-
stance abuse, patient refusal or loss to follow-up [29].
Health Outcomes
Chronic HCV negatively impacts patients’ quality of life. To
include this important aspect of the disease, we obtained health-
state utilities by combining several published studies [10,30,31,
32,33]. There is significant variability among the HCV health-
state utility research. We combined estimates to form a consistent
set of utilities for all fibrosis stages, HCC, transplant, and post-
SVR (see section II in Appendix S1). We modeled utility
decrements from biopsy as a one-time disutility of 20.05
(equivalent to a loss of 18 days), standard treatment for one year
as 20.11 (equivalent to a loss of 40 days) [30], and assumed
20.165 for one year of triple therapy (equivalent to a loss of 60
days). Decrements were scaled by the actual time on treatment.
Because of the variability in estimates, in sensitivity analyses, we
widely varied these utilities (see sections II, IV in Appendix S1).
(Table 3)
Costs
We included the costs of FibroTest, liver biopsy, treatment, and
annual medical care for patients with chronic HCV. FibroTest
and liver biopsy costs were obtained from the published literature
[8,34]. Treatment costs include drug cost and medical care cost.
To estimate drug costs, we assumed patients received peginter-
feron alfa-2b 150 mcg once weekly ($584/week, PegIntron
TM,
Schering Corp.; and similarly $580/week, 180 mcg once weekly of
peginterferon alfa-2a, PegasysH, Roche), plus ribavirin 1,000 mg
daily ($370.87/week, RebetolH, Schering Corp.) [35,36], convert-
ing these average wholesale prices to average manufacturer prices
using a 0.41 conversion factor [37]. We assumed a medical care
cost related to treatment of $10,740 per year based on chronic
HCV medical claims data [38]. The cost of telaprevir is reported
as $49,200 ($4,100 per week for 12 weeks) for the additional cost of
adding telaprevir to standard treatment in a three drug regime
[39]. (Table 3)
We estimated the annual care of fibrosis (no treatment) based on
medical expenditures in the year following hepatitis C diagnosis
[40]. We assumed that patients who obtained SVR post-treatment
incurred half of the pre-treatment annual care cost in their
Table 2. Model Parameter Values: Screening and Treatment Response Characteristics.
Base Min Max Source
Screening Test Characteristics
FibroTest (FibroSure)
Probability for patients with F0–F1 [6,8,19,20]
Test + (.0.58) 0.13 0.06 0.15
Test 2 (,0.31), specificity at 0.31 0.68 0.57 0.72
Probability for patients with F2–F4
Test + (.0.58), sensitivity at 0.58 0.56 0.35 0.59
Test 2 (,0.31) 0.16 0.12 0.29
Liver biopsy screening frequency (year) 3 3 5 [47]
Treatment Response Probability
Standard treatment (peginterferon and ribavirin)
Probability(EVR at 12 week), genotype 1 0.71 0.66 0.76 [28]
Probability(SVR | EVR), genotype 1 0.63 0.57 0.69 [28]
Probability(SVR), genotype 2 and 3 0.80 0.60 1.00 [1,10,28,34]
Triple therapy (peginterferon+ribavirin+telaprevir), genotype 1
a [9]
Probability(virologic failure at 12 week) 0.03
Probability(eRVR+, 24 week treatment | non-failure at 12 week) 0.60
Probability(eRVR2, 48 week treatment | non-failure at 12 week) 0.35
Probability(SVR|eRVR+, 24 week treatment) 0.89
Probability(SVR|eRVR2, 48 week treatment) 0.67
Noncompliance 0 0 0.63 [29]
aThe effectiveness listed for triple therapy are for patients with fibrosis stage F0 to F2; for patients with fibrosis stage F3 and F4, SVR is reduced by 20%.
doi:10.1371/journal.pone.0026783.t002
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in sensitivity analyses [10,38,40,41,42].
In cost calculations, we adopted a payer perspective, including
all direct health care costs, but excluding patient time and
transport. We discounted future costs and QALYs by 3%
annually. Costs are inflation adjusted using the Consumer Price
Index to 2009 [43].
Results
Among liver fibrosis screening options, strategies using FibroT-
est are more cost-effective than using Liver Biopsy Only (the
current recommended practice) for both men and women with
HCV genotype 1, 2, and 3.
As the current practice in the U.S. is to ascertain that a
patient has significant fibrosis progression prior to initiating
HCV treatment, especially relevant for genotype 1 patients, we
first considered the cost-effectiveness of screening-based strate-
gies only, finding that FibroTest Only costs less and is more
effective than Liver Biopsy Only. FibroTest and Biopsy has an
ICER of $347,600 compared to FibroTest Only for men and
$396,000/QALY for women with genotype 1 (Figure 4), both
exceeding thresholds typically used to define cost-effectiveness
($50,000–$100,000/QALY). For patients with genotypes 2 and
3 (Figure 5), FibroTest and Biopsy has an ICER of $29,900/
QALY for men and $31,100/QALY for women compared to
FibroTest Only. FibroTest and Biopsy is only cost-effective for
genotype 2 and 3 patients due to the greater likelihood of their
response to treatment. Consequently, the extra liver biopsy and
opportunity to initiate treatment based on its results offer more
benefits to genotype 2 and 3 patients compare to genotype 1
patients.
Table 3. Model Parameter Values: Quality Weights and Cost.
Base Min Max Source
Quality (utilities)
a [10,30,31,32,33]
Mild chronic HCV (F0, F1) 0.98 0.70 1.00
SVR following mild HCV 1.00 0.74 1.00
Moderate chronic HCV (F2, F3) 0.85 0.66 1.00
SVR following moderate HCV 0.93 0.71 1.00
Compensated cirrhosis (F4) 0.79 0.46 1.00
SVR following F4 0.93 0.60 1.00
Decompensated cirrhosis 0.72 0.26 0.91
HCC 0.72 0.15 0.95
Liver transplant
b 0.81 0.64 1.00
Liver biopsy decrement
c 20.05 20.20 0 Assumed
Treatment decrement (standard treatment)
c 20.11 20.20 0
Treatment decrement (triple therapy)
c 20.055 20.11 0 Assumed
Cost (2009 USD)
Screening test
Liver biopsy $1,415 $974 $1,623 [8,34]
FibroTest (FibroSure) $236 $100 $295 [8]
Treatment (peginterferon and ribavirin + medical care) [10,35,38,41]
No EVR, genotype 1 (12 weeks) $7,383 $5,605 $9,020
SVR, genotype 1 (48 weeks) $29,530 $22,420 $36,080
SVR, genotype 2 and 3 (24 weeks) $14,765 $11,812 $22,950
Treatment (telaprevir drug cost for 12 weeks) $49,200 $36,828 $59,040 [39,53]
Cost of annual care
d [10,38,40,41,42]
HCV no fibrosis (F0) $1,610 $150 $2,000
HCV portal fibrosis (F1, F2) $1,610 $150 $2,000
HCV bridging fibrosis (F3) $1,610 $150 $2,000
Compensated cirrhosis (F4) $1,610 $150 $2,000
Decompensated cirrhosis (DC) $10,930 $5,470 $16,400
HCC $43,510 $21,760 $65,270
Liver transplant, first year $143,290 $71,650 $214,930
Liver transplant, subsequent $25,020 $12,510 $37,540
aThe quality of life weight for a given age and HCV disease state is computed as the product of the utility associated with the HCV disease state and a mean age-specific
quality weight obtained from published data [54,55].
bAssumed the utility in the post liver transplant state is the same as the utility in F0 state.
cUnlike other utilities these decrement are short-term—only the time period when the intervention occurs.
dBaseline healthcare cost by age is included in the model [56].
doi:10.1371/journal.pone.0026783.t003
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forgoing screening altogether and initiating treatment regardless of
fibrosis stage, we find such a strategy cost-effective compared to
fibrosis screening (Table 4), with ICERs of $5,400/QALY for men
and $6,300/QALY for women with genotype 1 compared to
FibroTest Only. All other screening strategies provide less health
benefits and cost more. For patients with genotypes 2 or 3, all
screening strategies provide less health benefits and cost more.
The current gold standard, Liver Biopsy Only, provides less
health benefit and costs more than strategies using FibroTest or
Immediate Treatment across a broad range of assumptions.
However, if we consider only screening strategies that include liver
biopsy as part of their algorithm, for genotype 1, Liver Biopsy
Only is cost-effective compared to FibroTest Rule In (ICER of
$29,800/QALY for men and $57,200/QALY for women). For
genotypes 2 or 3, Liver Biopsy Only has an ICER below $10,000/
QALY compared to FibroTest Rule In.
If telaprevir were added to standard treatment in response-
guided triple therapy for genotype 1 patients, we find that
Immediate Treatment remains cost-effective compared to Fi-
broTest Only based on our assumption of the cost and disutility of
telaprevir triple therapy, with an ICER of $27,200/QALY for
men and $30,000/QALY for women. (Figure 6) Considering only
screening-based strategies but using the new triple therapy,
FibroTest Only is cost-effective with an ICER of $21,200/QALY
for men and $26,100/QALY for women compared to FibroTest
Rule In. (Table 5)
Additional base case results can be found in section III in
Appendix S1.
Sensitivity Analyses
Immediate Treatment consistently provided greater health
benefit per unit cost compared to the other strategies in one-way
sensitivity analyses for all model parameters. In two-way and
three-way sensitivity analyses, Immediate Treatment remained the
preferred strategy (section IV in Appendix S1). The same
conclusion holds for scenario analyses examining patient cohorts
aged 50 to 70 years old, increased mortality risks from other
Figure 4. Cost-effectiveness Results by Gender, Genotype 1 under Standard Treatment (exclude Immediate Treatment): (A) Men;
(B) Women.
doi:10.1371/journal.pone.0026783.g004
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characteristics, reduced SVR for patients with F3 and F4, and a
broad range of health utilities estimates (section IV in Appendix
S1). For example, while some would argue that older genotype 1
patients should be managed conservatively (i.e., a strategy like ‘‘Do
Nothing’’), we found that for those 70 year-olds with base case
fibrosis stage assumption, treatment is still cost-effective though its
ICER is higher (Table 6, $31,600/QALY, men).
If treatment was ultimately not given to 100% of eligible
patients due to loss to follow-up post screening or medical
contraindications discovered post-screening, Immediate Treat-
ment is even more strongly preferred as periodic screening
requires resource investment even for those patients who
ultimately do not begin treatment.
Immediate Treatment is preferred to screening-based approach-
es in a probabilistic sensitivity analysis (PSA) (section IV in
Appendix S1). Across 10,000 population simulations, at a
willingness-to-pay threshold of $50,000/QALY, Immediate Treat-
ment is the preferred strategy more than 99% of the time for both
men and women and for all genotypes under standard treatment.
For genotype 1 patients under triple therapy using telaprevir, at a
willingness-to-pay threshold of $50,000/QALY, Immediate Treat-
ment is the preferred strategy more than 90% of the time for men,
and more than 78% of the time for women.
Discussion
For eligible men and women with chronic HCV of genotype 1,
2, and 3 in the United States, treatment without screening to
determine liver fibrosis stage is cost-effective compared to periodic
fibrosis screening strategies. Because there may be additional
benefits to fibrosis staging prior to treatment (i.e., initiating
hepatocellular carcinoma screening for patients with advanced
fibrosis) and thus some clinicians may not consider treatment
Figure 5. Cost-effectiveness Results by Gender, Genotype 2 and 3 (exclude Immediate Treatment): (A) Men; (B) Women. Note: The
incremental cost-effectiveness ratio (ICER) is defined as the ratio of the additional costs of an intervention and its additional effects as comparedt o
the next best alternative. i.e. The ICER shown on the figures is between FibroTest Only and FibroTest and Biopsy.
doi:10.1371/journal.pone.0026783.g005
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alone is the next best alternative, and is more effective and less
costly than fibrosis screening with liver biopsies. Compared to
FibroTest alone, using FibroTest with biopsy reserved for patients
with intermediate results has an ICER above $100,000/QALY for
genotype 1 and below $50,000/QALY for other HCV genotypes.
These finding are robust to multiple assumptions and sensitivity
analyses.
This study addresses two important questions — whether to use
and how to use non-invasive makers of fibrosis instead of liver
biopsy to determine a patient’s need for treatment, and the
optimal timing to initiate treatment. Many clinicians have shown
aversion to non-invasive biomarkers due to the tests’ low sensitivity
and specificity. Some are concerned that biomarkers fail to make
accurate distinctions between mild and severe fibrosis and believe
that biopsy may inform treatment decisions in these mid-zones.
On the other hand, the apparent failure of serologic markers to
distinguish between intermediate stages can be the consequence of
classification errors from biopsy - several published studies suggest
that when biopsy and marker results are discordant, diagnostic
failure of biopsy is much more common than diagnostic failure of
biomarkers [44]. Decisions to perform biopsy may depend more
on physician preference than on the ability of liver biopsy to
influence treatment decisions [45,46,47]. We acknowledge the on-
going debate around the validity of FibroTest versus that of liver
biopsy. However, we find that despite the uncertainties associated
with FibroTest’s test characteristics, FibroTest Only strategy is
preferred over liver biopsy across a broad range of sensitivities and
specificities because of its advantage in cost, side effect, and
frequency of follow-up. Patients afraid of liver biopsy’s side effects
may be more accepting of non-invasive tests and consequently
these tests may also increase adherence to periodic fibrosis
assessment if treatment is withheld. Furthermore, treating all
patients (F0–F4) is often cost-effective and therefore distinguishing
between mild and significant fibrosis may not be not essential.
Our results contribute to the current debate regarding liver
biopsy. Many clinicians recognize liver biopsy’s disadvantages. In
addition to its cost and risk of adverse effects, liver biopsy is subject
to sampling errors (biopsy with a length of 25 mm has a
misclassification rate of 25%) [48]. Repeating biopsy every 3–5
years may also be unrealistic due to provider variability and
patient non-adherence. Despite this, the National Institute of
Health (NIH) 2002 Consensus Statement indicates that liver
biopsy still provides unique information on fibrosis and histology,
and no panel of serologic markers can provide an accurate
assessment of intermediate stages of fibrosis [14]. Similarly, the
2009 American Association for the Study of Liver Diseases
(AASLD) guideline recommends liver biopsy in making treatment
decisions [1]. However, it recognizes the usefulness of non-invasive
tests in defining the presence or absence of advanced fibrosis. Both
of the guidelines agree that liver biopsy is not necessary in
managing genotype 2 or 3 patients, since their treatment success
Table 4. Cost-Effectiveness Results by Gender and Genotype, Standard Treatment.
Genotype 1 Cost (US, $) QALY ICER ($/QALY)
Men FibroTest Only 193,979 15.01 –
FibroTest Rule In 194,447 14.82 dominated
Immediate Treatment 194,514 15.10 5,400
FibroTest and Biopsy 194,950 15.01 dominated
Liver Biopsy Only 195,169 14.85 dominated
FibroTest Rule Out 196,182 14.84 dominated
Women FibroTest Only 213,525 16.19 –
FibroTest Rule In 213,901 16.00 dominated
Immediate Treatment 214,101 16.28 6,300
FibroTest and Biopsy 214,557 16.19 dominated
Liver Biopsy Only 214,760 16.01 dominated
FibroTest Rule Out 215,987 16.01 dominated
Genotype 2&3 Cost (US, $) QALY ICER ($/QALY)
Men Immediate Treatment 187,547 16.69 –
FibroTest Only 188,070 16.51 dominated
FibroTest and Biopsy 189,048 16.54 dominated
FibroTest Rule In 190,455 16.23 dominated
Liver Biopsy Only 191,077 16.32 dominated
FibroTest Rule Out 192,021 16.30 dominated
Women Immediate Treatment 207,829 17.81 –
FibroTest Only 208,296 17.64 dominated
FibroTest and Biopsy 209,388 17.67 dominated
FibroTest Rule In 211,118 17.35 dominated
Liver Biopsy Only 211,953 17.44 dominated
FibroTest Rule Out 213,109 17.42 dominated
(ICER: incremental cost-effectiveness ratios. dominated: strategy costs more but achieves less QALY than the previous strategy or a combination of strategies).
doi:10.1371/journal.pone.0026783.t004
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future amendments to these guidelines, we find that even for
genotype 1 patients, both immediate treatment and non-invasive
screening appear cost-effective compared to liver biopsy. Further-
more, with the anticipated improvement in treatment success rate
for genotype 1 patients, guidelines may soon be revised.
Our results suggest that re-examination of the necessity of
screening prior to treatment decision may be appropriate. If
treatment is generally effective, additional information obtained
via screening may not provide sufficient additional value in
guiding clinical decisions, since even with fibrosis stage uncertain-
ty, treatment is likely to be sufficiently beneficial [45,46]. Our
research helps to map out this trade-off between fibrosis stage
accuracy and treatment success rate. Though no randomized
controlled trials proving that HCV antiviral therapy is associated
with long-term clinical benefits, there is a broad literature that
strongly suggests this relationship. The lack of long-term evidence
may be due to the slow progression of the disease and the short
history of the new combination therapy. We found immediate
treatment to be cost-effective, given the current treatment
effectiveness and anticipated improvements in the future [9].
Our results anticipate new anti-HCV drugs such as telaprevir and
boceprevir becoming available that may significantly improve
SVR for genotype 1 patients. Even with significantly increased
drug costs and potentially increased risk of side-effects, our
analyses support immediate treatment without fibrosis screening.
Our analyses and conclusions were robust to a variety of
assumptions. Importantly, our conclusions were not sensitive to
uncertainties regarding the speed of fibrosis progression and
proportion of non-progressors in the cohort. As cost-effectiveness is
also influenced by health utilities of HCV health states used in the
model, our main conclusion remained robust despite uncertainties
regarding these estimates. We also note depending on who is the
payer, the cost of treatment can be much lower than our current
Figure 6. Cost-effectiveness Results by Gender, Genotype 1 under Triple Therapy with Telaprevir: (A) Men; (B) Women.
doi:10.1371/journal.pone.0026783.g006
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in which case immediate treatment would appear even more
favorable.
Previous research examined the economic outcomes of non-
invasive testing in the diagnosis of significant liver fibrosis compared
withliverbiopsy and recommended against non-invasivetesting[8].
The conclusion is made with the assumption that ‘‘misdiagnosis’’
leading to early treatment is harmful to health. The assumption is
problematic by disregarding all future benefits and cost. By
evaluating a one-time use of non-invasive test, the study ignored
one major advantage of non-invasive test that enables more
frequent monitoring of fibrosis progression than liver biopsy.
Our study has several limitations. The model does not stratify
the population by race, and thus the fibrosis progression and
treatment response rates are biased towards whites reflecting the
participants in the clinical studies of our source data. Because
needed information on genotypes other than 1, 2, and 3 was
limited, the model only considers clinical scenarios for genotypes
1, 2, and 3, which is appropriate for a U.S. analysis where these
types are most common. We did not consider co-infection with
HIV and/or hepatitis B. We defined alternative screening
strategies by possible combinations of FibroTest and liver biopsy.
Our strategy set is not comprehensive, and we note other
screening patterns exist. We did not consider other non-invasive
markers and imaging methods such as FibroScan to evaluate liver
stiffness. However, for non-invasive tests that are conducted at
similar intervals, that have comparable test characteristics and that
have comparable costs to FibroTest, our conclusion are also
Table 5. Cost-Effectiveness Results by Gender and Genotype, Triple Therapy with Telaprevir.
Genotype 1 Cost (US, $) QALY ICER ($/QALY)
Men FibroTest Rule In 230,651 15.58 –
Liver Biopsy Only 232,502 15.63 dominated
FibroTest Rule Out 233,499 15.63 dominated
FibroTest Only 236,167 15.84 21,200
FibroTest and Biopsy 237,482 15.86 dominated
Immediate Treatment 240,240 15.99 27,200
Women FibroTest Rule In 248,603 16.69 –
Liver Biopsy Only 250,611 16.74 dominated
FibroTest Rule Out 251,762 16.73 dominated
FibroTest Only 255,660 16.96 26,100
FibroTest and Biopsy 257,002 16.98 dominated
Immediate Treatment 259,853 17.10 30,000
(ICER: incremental cost-effectiveness ratios. dominated: strategy costs more but achieves less QALY than the previous strategy or a combination of strategies).
doi:10.1371/journal.pone.0026783.t005
Table 6. Incremental Cost-Effectiveness Ratios ($/QALY) by Cohort Starting Age, Genotype 1 under Standard Treatment, Base Case
Fibrosis Stage Distribution.
Men, Age 40 50 60 70
Do Nothing ––––
FibroTest Only ED ED ED ED
FibroTest and Biopsy DDDD
FibroTest Rule In DDDE D
FibroTest Rule Out DDDD
Liver Biopsy Only DDDD
Immediate Treatment $12,100/QALY $14,800/QALY $19,900/QALY $31,600/QALY
Women, Age 40 50 60 70
Do Nothing ––––
FibroTest Only ED ED ED ED
FibroTest and Biopsy DDDD
FibroTest Rule In DDE D E D
FibroTest Rule Out DDDD
Liver Biopsy Only DDDD
Immediate Treatment $13,100/QALY $15,900/QALY $20,700/QALY $31,000/QALY
(D: dominated, ED: Extended-Dominated by a combination of Do Nothing and Immediate Treatment).
doi:10.1371/journal.pone.0026783.t006
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determine liver fibrosis stage would be cost-effective compared to
periodic screening strategies. This result was robust to a wide
range of sensitivities, specificities, and test costs, and should,
therefore, hold for many other non-invasive markers.
Depending on who bears the cost of new antiviral drugs,
patients may prefer to wait to initiate treatment until there is
evidence of significant fibrosis progression. The model did not
include possible future advances in treatment in the base case
analysis and allow patients to delay treatment for a later date. The
analyses also did not include the benefits of fibrosis screening to
patients being able to make an informed choice and, therefore,
potentially having a stronger commitment to treatment adherence.
HCV is a serious liver disease affecting up to 4 million
Americans. While current recommendations favor liver biopsies
prior to treatment initiation, we find that, for the hundreds of
thousands of Americans with chronic HCV, other strategies are
likely more effective and cost-effective. Management of chronic
HCV in the U.S. could be improved by a shift towards strategies
that initiate immediate treatment without fibrosis screening or else
periodic screening with a non-invasive method followed by
treatment for those found likely to have significant fibrosis.
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